Author:
Castiglione-Gertsch M,Tattersall M,Hacking A,Goldhirsch A,Gudgeon A,Gelber R.D,Lindtner J,Coates A,Collins J,Isley M,Senn H.-J,Rudenstam C.-M
Reference15 articles.
1. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992, 339, 1–15, 71–85.
2. A mathematical model of relating the drug-sensitivity of tumours to their spontaneous mutation rate;Goldie;Cancer Treat Rep,1979
3. New information on drug resistance. Implications for the adjuvant treatment of breast cancer;Goldie;Recent Results Cancer Res,1989
4. Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol 1989, 7, 36–44.
5. Valagussa P, Tancini G, Bonadonna G, et al. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986, 58, 1411–1417.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献